

PRODROMAL SYMPTOMS AS VALID PREDICTORS OF RELAPSE IN SCHIZOPHRENIC DISORDERS

Thesis

Submitted for Partial Fulfillment of
M.D. Degree
in
PSYCHIATRY

By
Amany Haroun El-Rasheed Abd El-Hameed



Supervised by

Prof. Dr. Ahmed Okasha

*Professor of Psychiatry
Faculty of Medicine
Ain Shams University*

Prof. Dr. Zeinab Bishry

*Professor of Psychiatry
Faculty of Medicine
Ain Shams University*

Prof. Dr. Mohamed Rifaat El-Fiki

*Professor of Psychiatry
Faculty of Medicine
Ain Shams University*

**Faculty of Medicine
Ain Shams University
1996**





قالوا

يَسُبُّكَ يَا لَيْلَى الْإِمَامُ الْكَبِيرُ
إِنَّكَ أَنْتَ الْعَالِمُ الْحَكِيمُ

صَدَقَ اللَّهُ الْعَظِيمُ

سورة العنكبوت (الآية ٢٢)



To...

My Parents

Amany

Acknowledgement

I would like to express my deepest gratitude to Prof. Dr. Ahmed Okasha, Professor of Psychiatry, Ain Shams University; Prof. Dr. Zeinab Bishry, Professor of Psychiatry, Ain Shams University; and to Prof. Dr. Mohamed Rifaat El-Fiki, Professor of Psychiatry, Ain Shams University, for their guidance, encouragement and constructive criticism on revising the manuscript that made the work more meaningful.

I would like also to express my appreciation to Prof. Dr. Mostafa Kamel, Professor and Head of Neuropsychiatric Department, Ain Shams University; Prof. Dr. Adel Sadek, Professor of Psychiatry, Ain Shams University; Prof. Dr. Farouk Lotaief, Professor of Psychiatry, Ain Shams University; and to Prof. Dr. Mohamed Ghanem, Professor of Psychiatry, Ain Shams University, for their enthusiastic support.

No words can express my gratitude to My Parents, without their help this work would have never been completed to its current form.

Amany Haroun

CONTENTS

	Page
INTRODUCTION	1
AIM OF THE WORK	3
REVIEW OF LITERATURE	4
• Natural history of schizophrenia	4
• Prodroma of relapse in schizophrenia	22
• Relapse in schizophrenia	31
• Possible factors influencing relapse in schizophrenia	53
• Role of antipsychotic drugs in relapse prevention in schizophrenia	67
• Role of life events in relapse in schizophrenia	126
• Role of expressed emotion (EE) in relapse in schizophrenia	144
• Psychoeducational family therapy	161
• Summary of management and prevention of relapse	187
SUBJECTS AND METHODS	197
RESULTS	215
DISCUSSION	299
• Discussion of some important issues in the review of literature	299
• Discussion of the results of the present study	308
RECOMMENDATIONS	341
SUMMARY	348
REFERENCES	354
APPENDICES	--
I. The Arabic version of the used questionnaire for prodromal symptoms assessment	--
II. Arabic version of the "Social Readjustment Rating Scale"	--
III. Diagnostic values of the individual prodromal symptoms studied	--
ARABIC SUMMARY	--

LIST OF FIGURES

Fig. No.	Title	Page
L1	Schematic representation of long-term course in schizophrenia	10
L2	The natural history of schizophrenia	11
L3	Stress-vulnerability of schizophrenia and some preventative and therapeutic interventions	45
L4	A heuristic conceptual framework for possible factors in the development of schizophrenic episodes	60
L5	Multivariate model for predictors of relapse and early course in schizophrenia	62
L6	The health belief model of compliance	94
L7	A vulnerability model of schizophrenia	132
L8	Proposed relationship between vulnerability and stressors as influences on schizophrenia	136
L9	Relapse rates from 5 studies contrasting a family intervention program with its absence	175
R1	Age at onset of schizophrenic disorders in R and NR	225
R2	Total duration of hospitalization in R and NR	228
R3	Duration of non-compliance in R and NR	233
R4	Number of episodes in males (in R and NR)	242
R5	Number of episodes in females (in R and NR)	243
R6	Life events scores in R, NR and HC	249
R7	Life events scores in compliant vs non-compliant R	262
R8	Life events scores in compliant vs non-compliant NR	263

LIST OF TABLES

Tab. No.	Title	Page
L1	The six types of long-term course in schizophrenia and their frequency in the Cologne study	10
L2	Patterns of course of schizophrenia in Madras Longitudinal Study	12
L3	Distribution of schizophrenic patients assessed at 5-year follow-up by pattern of course	13
L4	The proportion of patients with a 'favourable' outcome in various long-term studies of schizophrenia	16
L5	Factors predisposing to various aspects of outcome in schizophrenic patients	20
L6	Proportion of non-relapsers	40
L7	Possible factors influencing relapse in schizophrenic patients	44
L8	Relapse rate following drug discontinuation among patients in long-term remission	70
L9	One-year placebo-controlled studies on the efficacy of neuroleptic relapse prevention in schizophrenia	71
L10	Reason for noncompliance in schizophrenic patients	82
L11	Advantage of depot neuroleptics	107
L12	Clinical application of intermittent treatment	123
L13	Contraindications to the use of intermittent medication	124
L14	Criteria for a high EE rating	146
L15	Factors affected and not affected by a brief family education program	167
L16	Schematic intervention package by severity	196
S1	Characteristics of the patients in the pilot study	206
S2	Agreements and disagreements on the items of the Arabic version of the used questionnaire	206
S3	Definitions of basic predictive characteristics	214
R1	Sex distribution	215
R2	Age distribution	216
R3	Comparison regarding the age	217
R4a	Marital status	218
R4b	Statistical calculations regarding marital status	218

R5	Having children or not	219
R6	Level of education	220
R7	Residence	221
R8a	Employment state	222
R8b	Employment grade	222
R9	Number of previous hospitalization	223
R10	Age at onset	224
R11	Age at first hospitalization	226
R12	Number of hospitalization	226
R13	Total duration of hospitalization	227
R14	Admission state	229
R15a	Treatment status	230
R15b	Compliance state	231
R16	<i>Duration of non-compliance</i>	231
R17a	Distribution of patients among subtypes of schizophrenia	234
R17b	Statistical calculation regarding the distribution among different subtypes of schizophrenia	235
R18	Distribution of different subtypes according to sex in R	236
R19	Statistical calculation regarding the distribution of different subtypes of schizophrenia according to sex in R	236
R20a	Distribution of different subtypes according to sex in NR	237
R20b	Statistical calculation of the distribution of different subtypes according to sex in NR	238
R21a	Number of episodes in relation to subtype	238
R21b	Statistical calculation regarding the number of episodes in relation to subtype	239
R22a	Number of episodes in relation to sex	240
R22b	Statistical calculation regarding the number of episodes in relation to sex	241
R23	Frequencies, Rank, chi-squares, P-value of life events of SRRS	245
R24	Life events scores	248
R25a	Life events scores according to sex	250
R25b	Statistical calculation of life events scores according to sex	251
R26a	Life events scores according to marital status in R	252
R26b	Statistical calculation of life events scores according to marital status in R	253
R27a	Life events scores according to marital status in NR	254

R27b	Statistical calculation of life events scores according to marital status in NR	255
R28a	Life events scores according to marital status in HC	256
R28b	Statistical calculation of life events scores according to marital status in HC	257
R29a	Life events scores in relation to compliance state in R	258
R29b	Life events scores in relation to compliance state in NR	259
R30a	Life events scores in compliant vs non-compliant R and NR	260
R30b	Primary statistical calculation regarding life events scores in compliant vs non-compliant R and NR	261
R31	Frequencies, rank, chi-squares, and p-values of different prodromal symptoms in R compared to NR	265
R32	Frequencies, rank, chi-squares, and p-values of different prodromal symptoms in R compared to HC	266
R33	Frequencies, rank, chi-squares, and p-values of different prodromal symptoms in different subtypes of schizophrenia in R	273
R34	Frequencies, rank, chi-squares, and p-values of different prodromal symptoms in different subtypes of schizophrenia in NR	276
R35	Comparison between results of the used questionnaire in R, NR and HC	278
R36	Comparison between results of the used questionnaire in R, NR and their relatives	279
R37	Comparison between results of the used questionnaire in R, and the relatives in different subtypes of schizophrenia	280
R38	Comparison between results of the used questionnaire in NR, and their relatives in different subtypes of schizophrenia	281
R39a	Paranoid schizophrenics	282
R39b	Disorganized schizophrenics	282
R39c	Undifferentiated schizophrenics	283
R40	Diagnostic values of the used questionnaire in R compared to NR and HC	285
R41	Diagnostic values of the suggested questionnaire form if it contains the most frequent prodromal symptoms in R and their relatives compared to NR or HC	286

R42	Diagnostic values of the suggested questionnaire form if it contains the most frequent prodromal symptoms in R and at the same time least frequent in NR or HC	288
R43	Diagnostic values of the suggested questionnaire form if it contains the most frequent prodromal symptoms according to relatives of R and at the same time least frequent in NR or HC	290
R44	Diagnostic values of the suggested questionnaire form if it contains the HS only or HS and S prodromal symptoms in R compared to NR or HC	293
R45	Diagnostic values of the suggested questionnaire form if it contains the HS only or HS and S prodromal symptoms according to relatives of R compared to NR or HC	294
R46	Diagnostic values of the suggested questionnaire form if it contains the shared HS only or HS and S prodromal symptoms according to R and their relatives compared to NR or HC	295
D1	Comparison between Atlanta study and the Egyptian study	311
D2	Comparison between Buffalo study and the Egyptian study	312

ABBREVIATIONS

BFM	Behavioral family management
BPRS	Brief Psychiatric Rating Scale
CGI	Clinical Global Impression
CSE	Coping Strategy Enhancement
CSF	Cerebrospinal fluid
CNS	Central nervous system
D2 receptors	Dopaminergic receptors type 2
DA	Dopamine
DS	Discordant score
DSM-I	Diagnostic and Statistical Manual of Mental Disorders First Edition.
DSM-II	Diagnostic and Statistical Manual of Mental Disorders Second Edition.
DSM-III	Diagnostic and Statistical Manual of Mental Disorders Third Edition.
DSM-III-R	Diagnostic and Statistical Manual of Mental Disorders Third Revised Edition.
DSM-IV	Diagnostic and Statistical Manual of Mental Disorders Fourth Edition.
EE	Expressed emotion
EOI	Emotional over-involvement
ESQ	Early Sign Questionnaire
G	Group
GAS	Global Assessment Scale
GP	General practitioner
HC	Healthy control
HEE	High expressed emotion
HR	Heart Rate
HS	Highly significant
HVA	Homovanillic acid
IPSS	International Pilot Study of Schizophrenia
LCU	Life change unit
LEE	Low expressed emotion
N or No	Number
NIDS	Neuroleptic induced deficit syndrome
NIMH	National Institute of Mental Health

NR	Non-relapsing patients
NS	<i>Non-significant</i>
NS-SCRs	Non-specific skin conductance responses
PAR	Proportional attributable risk
PBI	Parental Bonding Instrument
PE-MFP	Psycho-educational multiple family programs
PPR	Psychophysiological reactivity
PPV	Positive predictive value
PV -ve	Predictive value of negative
PV +ve	Predictive value of positive
R	Relapsing patients
RLE	Recent life experiences
SCL	Skin conduction latency
SRRQ	Social Readjustment Rating Questionnaire
SRRS	Social Readjustment Rating Scale
T0	Time zero
TD	Tardive dyskinesia
TSS	Treatment strategies study
vs	Versus
WHO	World Health Organization

**INTRODUCTION
AND
AIM OF THE WORK**

INTRODUCTION

It is a well known fact that relapse of schizophrenic disorders takes a toll on patients and their families and imposes a financial burden on hospitals and community resources (Davies and Drummond, 1993).

It is worth mentioning that in the last 40 years, the treatment and, above all, the prophylaxis of schizophrenic psychosis has made great progress due to the introduction of the neuroleptics and the use of psychosocial treatment strategies. Unfortunately, the potentialities inherent in neuroleptic relapse prevention are far from being fully utilized. As a consequence, the relapse rate for this severe mental illness is still three times higher than it ought to be (Kissling, 1994). However, if the unnecessarily high relapse rate for schizophrenic patients is to be reduced, the development and implementation of preventive treatment programmes must be given top priority. Significantly more time, personnels and money must be invested in relapse prevention. As is the case in many other medical problems (e.g. heart disease, diabetes), a marked reduction in the relapse rate of schizophrenia can only be achieved by comprehensive prophylactic programme involving patients, family members, and others responsible for care. They must be informed in detail about all aspects of relapse prevention, as well as being given consequent encouragement and support to actively take part in therapy. The positive effects of a psychoeducational approach on compliance and relapse rates have been demonstrated by Smith and Birchwood (1990).